Individuals with PD were enrolled if they were within 2 years of diagnosis, Hoehn and Yahr (H&Y) stage 1–2, not on PD medications at the time of enrollment, and had an abnormal dopamine transporter (DAT) imaging scan with single-photon-emission computed tomography (SPECT). Here, SLC6A3 is linked to Parkinson disease.